It is well-known that HER2 status assessed by IHC (particularly score 2+) is not an optimal approach for selection of the patients having a mutant HER2 cancer as recently shown in case of colorectal carcinoma [38]. The gene discussed is ERBB2; the disease is colorectal carcinoma.